Neonatal screening for congenital hypothyroidism: more than 30 years of experience in the Netherlands

• Published in: Nederlands tijdschrift voor geneeskunde Vol. 158; p. A6564
• Main Authors: Verkerk, Paul H, van Trotsenburg, A S Paul, Hoorweg-Nijman, J J Gera, Oostdijk, Wilma, van Tijn, David A, Kempers, Marlies J E, van den Akker, Erica L T, Loeber, Jerard G, Elvers, L H Bert, Vulsma, Tom
• Format: Journal Article
• Language: Dutch
• Published: Netherlands 2014
• Subjects: Congenital Hypothyroidism - blood; Congenital Hypothyroidism - diagnosis; Female; Humans; Infant, Newborn; Male; Neonatal Screening - methods; Neonatal Screening - standards; Netherlands - epidemiology; Prevalence; Sensitivity and Specificity; Thyrotropin - blood; Thyroxine - blood; Thyroxine-Binding Proteins - analysis; Netherlands
• ISSN: 0028-2162; 1876-8784

To describe the Dutch neonatal screening programme for congenital hypothyroidism (CH). Descriptive study. Data on neonatal screening for CH in the period 1 January 1981 through 31 December 2011 were obtained from the Department for Vaccine Supply and Prevention Programmes of the Dutch National Institute for Public Health and the Environment (RIVM), laboratories and paediatricians to whom babies with abnormal screening results were referred. The screening procedure has been amended several times. In the period 1981-1994, only T4 and TSH were measured in heel prick blood, for example. From 1995, thyroxine-binding globulin (TBG) was added to the screening protocol. The participation rate was 99.7%. Before 1995 the sensitivity, specificity and positive predictive value were 94%, 99.51% and 6%, respectively. From 1995 these percentages were 98%, 99.85% and 21%, respectively. The total prevalence of CH was 1:2670 (prevalence of CH of thyroidal origin was 1:3100 and CH of central origin was 1:21,600). The percentages of patients with severe CH treated before day 15 in the periods 1981-1990, 1991-2000 and 2001-2011 were 24% (63/263), 63% (170/269) and 96% (176/184), respectively. The sensitivity and specificity of the screening procedure has considerably increased since 1995 compared with the period before 1995. In recent years patients with severe CH were treated considerably earlier than in the first years of the screening. Neonatal screening for CH may be considered as an important success for public health care.